DDInter610 DDInter1376
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour cells.[L12621,L12627] Durvalumab is marketed under the brand name Imfinzi, which is available for intravenous injections. It was granted accelerated approval by the FDA in May 2017 for the treatment of selected patients with locally advanced or metastatic urothelial carcinoma. In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1%
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Durvalumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Durvalumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Durvalumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Durvalumab {u} may lead to a major life threatening interaction when taken with {v} Tofacitinib
Durvalumab {u} may lead to a major life threatening interaction when taken with {v} Baricitinib
Durvalumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Durvalumab may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Durvalumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Durvalumab may lead to a major life threatening interaction when taken with Tofacitinib
Durvalumab may lead to a major life threatening interaction when taken with Baricitinib